97 related articles for article (PubMed ID: 34803447)
1. Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease.
Oktay L; Erdemoğlu E; Tolu İ; Yumak Y; Özcan A; Acar E; Büyükkiliç Ş; Olkan A; Durdaği S
Turk J Biol; 2021; 45(4):459-468. PubMed ID: 34803447
[TBL] [Abstract][Full Text] [Related]
2. Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target.
DurdaĞi S
Turk J Biol; 2020; 44(3):185-191. PubMed ID: 32595355
[TBL] [Abstract][Full Text] [Related]
3. Screening of FDA approved drugs for finding potential inhibitors against Granzyme B as a potent drug-repurposing target.
Ikram S; Ahmad J; Durdagi S
J Mol Graph Model; 2020 Mar; 95():107462. PubMed ID: 31786094
[TBL] [Abstract][Full Text] [Related]
4. Integrating Ligand and Target-Driven Based Virtual Screening Approaches With
Tutumlu G; Dogan B; Avsar T; Orhan MD; Calis S; Durdagi S
Front Chem; 2020; 8():167. PubMed ID: 32328476
[TBL] [Abstract][Full Text] [Related]
5. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
6. Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation.
Elekofehinti OO; Iwaloye O; Molehin OR; Famusiwa CD
In Silico Pharmacol; 2021; 9(1):49. PubMed ID: 34395160
[TBL] [Abstract][Full Text] [Related]
7. QSAR based virtual screening derived identification of a novel hit as a SARS CoV-229E 3CL
Jawarkar RD; Bakal RL; Zaki MEA; Al-Hussain S; Ghosh A; Gandhi A; Mukerjee N; Samad A; Masand VH; Lewaa I
Arab J Chem; 2022 Jan; 15(1):103499. PubMed ID: 34909066
[TBL] [Abstract][Full Text] [Related]
8. Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease.
Chowdhury KH; Chowdhury MR; Mahmud S; Tareq AM; Hanif NB; Banu N; Reza ASMA; Emran TB; Simal-Gandara J
Biology (Basel); 2020 Dec; 10(1):. PubMed ID: 33374717
[TBL] [Abstract][Full Text] [Related]
9. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
11. Novel AChE and BChE inhibitors using combined virtual screening, text mining and in vitro binding assays.
Sahin K; Zengin Kurt B; Sonmez F; Durdagi S
J Biomol Struct Dyn; 2020 Jul; 38(11):3342-3358. PubMed ID: 31462153
[TBL] [Abstract][Full Text] [Related]
12.
Ibrahim MAA; Abdelrahman AHM; Hegazy MF
J Biomol Struct Dyn; 2021 Sep; 39(15):5756-5767. PubMed ID: 32684114
[TBL] [Abstract][Full Text] [Related]
13.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
[TBL] [Abstract][Full Text] [Related]
15. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.
Zaka M; Abbasi BH; Durdagi S
J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845
[TBL] [Abstract][Full Text] [Related]
16. Virtual screening, drug-likeness analysis, and molecular docking study of potential severe acute respiratory syndrome coronavirus 2 main protease inhibitors.
Nedeljković NV; Nikolić MV; Stanković AS; Jeremić NS; Tomović DL; Bukonjić AM; Radić GP; Mijajlović MŽ
Turk J Chem; 2022; 46(1):116-146. PubMed ID: 38143877
[TBL] [Abstract][Full Text] [Related]
17. In Silico Prediction of Novel Inhibitors of SARS-CoV-2 Main Protease through Structure-Based Virtual Screening and Molecular Dynamic Simulation.
Halim SA; Waqas M; Khan A; Al-Harrasi A
Pharmaceuticals (Basel); 2021 Sep; 14(9):. PubMed ID: 34577596
[TBL] [Abstract][Full Text] [Related]
18. Molecular docking and simulation studies on SARS-CoV-2 M
Lokhande KB; Doiphode S; Vyas R; Swamy KV
J Biomol Struct Dyn; 2021 Nov; 39(18):7294-7305. PubMed ID: 32815481
[TBL] [Abstract][Full Text] [Related]
19. Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19).
De Vita S; Chini MG; Lauro G; Bifulco G
RSC Adv; 2020 Nov; 10(67):40867-40875. PubMed ID: 35519188
[TBL] [Abstract][Full Text] [Related]
20. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]